ClinicalTrials.gg
CompletedNCT00919867Updated Jun 14, 2021Results posted

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

A Phase 1 interventional study of SPD503 and VYVANSE in Healthy, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Drug-drug interaction study; to examine the pharmacokinetics of SPD503 and VYVANSE (lisdexamfetamine dimesylate) when given alone, and in combination.

02

Conditions studied

  • Healthy

Keywords

  • Normal, healthy volunteers (for this Phase 1 study)
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subjects must be normal healthy adult volunteers (with no significant abnormalities in medical history, physical exam, vital signs or lab evaluations at screening) in order to be eligible to participate.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    A: SPD503 (4mg)

    Drug: SPD503

  • Active comparator
    B: VYVANSE (50mg)

    Drug: VYVANSE

  • Active comparator
    C: SPD503 (4mg) + VYVANSE (50mg)

    Drug: SPD503 and VYVANSE

Interventions

  • DrugSPD503

    SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.

    Also known as: guanfacine hydrochloride

  • VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.

    Also known as: lisdexamfatamine dimesylate (LDX)

  • DrugSPD503 and VYVANSE

    Drug pages: Guanfacine · Lisdexamfetamine

    SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Guanfacine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  2. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  3. Time of Maximum Plasma Concentration (Tmax) of Guanfacine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  4. Time of Plasma Half-Life(T 1/2) of Guanfacine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  5. Cmax of d-Amphetamine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  6. AUC of d-Amphetamine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  7. Tmax of d-Amphetamine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

  8. T 1/2 of d-Amphetamine

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose

07

Results

Posted Aug 2, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneSPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503
Started777777
Completed776776
Not completed001001
Withdrew: Withdrawal by subject001000
Withdrew: Physician decision000001
Washout
Participant flow — Washout
MilestoneSPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503
Started776776
Completed776776
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneSPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503
Started776776
Completed776776
Not completed000000
Washout
Participant flow — Washout
MilestoneSPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503
Started776776
Completed776776
Not completed000000
Third Intervention
Participant flow — Third Intervention
MilestoneSPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503
Started776776
Completed776776
Not completed000000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Guanfacine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Guanfacine
ng/mlSPD503 AloneSPD503 + Vyvanse
Maximum Plasma Concentration (Cmax) of Guanfacine2.55 ± 1.032.97 ± 0.98
PrimaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · ng*h/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine
ng*h/mlSPD503 AloneSPD503 + Vyvanse
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Guanfacine104.9 ± 34.7112.8 ± 35.7
PrimaryTime of Maximum Plasma Concentration (Tmax) of Guanfacine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · hours
Time of Maximum Plasma Concentration (Tmax) of Guanfacine
hoursSPD503 AloneSPD503 + Vyvanse
Time of Maximum Plasma Concentration (Tmax) of Guanfacine8.6 ± 7.77.9 ± 5.0
PrimaryTime of Plasma Half-Life(T 1/2) of Guanfacine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · hours
Time of Plasma Half-Life(T 1/2) of Guanfacine
hoursSPD503 AloneSPD503 + Vyvanse
Time of Plasma Half-Life(T 1/2) of Guanfacine23.5 ± 10.221.4 ± 8.2
PrimaryCmax of d-Amphetamine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · ng/ml
Cmax of d-Amphetamine
ng/mlVyvanse AloneSPD503 + Vyvanse
Cmax of d-Amphetamine36.48 ± 7.1336.50 ± 6.00
PrimaryAUC of d-Amphetamine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · ng*h/ml
AUC of d-Amphetamine
ng*h/mlVyvanse AloneSPD503 + Vyvanse
AUC of d-Amphetamine686.9 ± 159.8708.4 ± 137.8
PrimaryTmax of d-Amphetamine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · hours
Tmax of d-Amphetamine
hoursVyvanse AloneSPD503 + Vyvanse
Tmax of d-Amphetamine4.2 ± 1.13.9 ± 1.1
PrimaryT 1/2 of d-Amphetamine
Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 48 and 72 hours post-dose
Reported as:
Mean · hours
T 1/2 of d-Amphetamine
hoursVyvanse AloneSPD503 + Vyvanse
T 1/2 of d-Amphetamine11.2 ± 1.611.2 ± 1.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD503 Alone—0/40 (0%)9/40 (22.5%)
Vyvanse Alone—0/41 (0%)6/41 (14.6%)
SPD503 + Vyvanse—0/41 (0%)6/41 (14.6%)
Most frequent other events
Most frequent other events
EventSPD503 AloneVyvanse AloneSPD503 + Vyvanse
Dizziness PosturalNervous system disorders4/401/410/41
HeadacheNervous system disorders3/402/413/41
DizzinessNervous system disorders2/403/413/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503Total
<=18 years0000000
Between 18 and 65 years77777742
>=65 years0000000
Age, Continuous
Age, Continuous(years)SPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503Total
Mean30.9 ± 6.2028.7 ± 8.4434.6 ± 10.1826.0 ± 5.2931.9 ± 8.1931.1 ± 4.1830.5 ± 7.41
Sex: Female, Male
Sex: Female, Male(Participants)SPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503Total
Female1122219
Male66555633
Region of Enrollment
Region of Enrollment(Participants)SPD503 First, Then Vyvanse, Then SPD503 + VyvanseSPD503 First, Then SPD503 + Vyvanse, Then VyvanseVyvanse First, Then SPD503, Then SPD503 + VyvanseVyvanse First, Then SPD503 + Vyvanse, Then SPD503SPD503 + Vyvanse First, Then SPD503, Then VyvanseSPD503 + Vyvanse, Then Vyvanse, Then SPD503Total
United States77777742
08

Study locations

1 site
  • Advanced Biomedical Research, Inc.
    Hackensack, New Jersey, United States
09

References and documents

Publications

  • Roesch B, Corcoran ME, Fetterolf J, Haffey M, Martin P, Preston P, Purkayastha J, Wang P, Ermer J. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8. PubMed 23615868 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2009 to primary completion in Jul 2009, 1 month.

Results were first posted in Aug 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2009
First posted
Jun 12, 2009
StartActual
Jun 24, 2009
Primary completionActual
Jul 30, 2009
CompletionActual
Jul 30, 2009
Results first posted
Aug 2, 2010
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00919867
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 12, 2009
Start date
Jun 24, 2009
Primary completion
Jul 30, 2009
Completion
Jul 30, 2009
Results posted
Aug 2, 2010
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guanfacine · Lisdexamfetamine

Start the discussion